`_____________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________
`
`
`NALOX-1 PHARMACEUTICALS, LLC,
`Petitioner,
`v.
`ADAPT PHARMA OPERATIONS LIMITED, AND
`OPIANT PHARMACEUTICALS, INC.
`Patent Owners.
`_____________________
`
`CASE IPR2019-00694
`U.S. Patent No. 9,629,965
`
`PETITIONER’S UPDATED MANDATORY NOTICES
`PURSUANT TO 37 C.F.R. § 42.8
`
`
`
`
`
`
`
`I.
`
`IPR2019-00694 – U.S. Patent No. 9,629,965
` Petitioner’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8
`
`Real Party-in-Interest Pursuant to 37 C.F.R. § 42.8(b)(1)
`
`Pursuant to 37 C.F.R. § 42.8(b)(1), Petitioner certifies that Nalox-1
`
`Pharmaceuticals, LLC, BCIM Partners III, LP, BCIM General Partner III, LP,
`
`Burford Capital Ireland DAC, BCIM PIII Holdings, LLC, Burford Capital
`
`Investment Management LLC, Burford Capital Holdings (UK) Limited, and Burford
`
`Capital Limited are the real parties in interest (collectively, “RPI”), and remains
`
`unchanged since Petitioner’s prior mandatory notices. Nalox-1 Pharmaceuticals,
`
`LLC, a Delaware limited liability company, is 100% owned by BCIM Partners III,
`
`LP, a Delaware limited partnership. BCIM General Partner III, LLC, a Delaware
`
`limited liability company, is the general partner of BCIM Partners III, LP, and
`
`Burford Capital Investment Management LLC is the investment manager to BCIM
`
`Partners III, LP. No other person has authority to direct or control (i) the timing of,
`
`filing of, content of, or any decisions or other activities relating to this Petition or
`
`(ii) any timing, future filings, content of, or any decisions or other activities relating
`
`to the future proceedings related to this Petition. All of the costs associated with this
`
`Petition are expected to be borne by Nalox-1 Pharmaceuticals, LLC, BCIM Partners
`
`III, LP, BCIM General Partner III, LP, Burford Capital Investment Management
`
`LLC and Burford Capital Holdings (UK) Limited.
`
`II. Related Matters Under 37 C.F.R. § 42.8(b)(2)
`Petitioner identifies the following judicial or administrative matters that
`
`AFDOCS/22424524.1
`
`
`
`
`IPR2019-00694 – U.S. Patent No. 9,629,965
` Petitioner’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8
`
`
`would affect, or be affected by, a decision in this proceeding: claims 7 and 9 of U.S.
`
`Patent No. 9,468,747; claim 4 of U.S. Patent No. 9,561,177; claims 21, 24, and 25
`
`of U.S. Patent No. 9,629,965; and claims 2, 24, 33, and 38 of U.S. Patent No.
`
`9,775,838 have all been held invalid in a case captioned Adapt Pharma Operations
`
`Ltd. et al. v. Teva Pharmaceuticals USA, Inc., C.A. No. 16-cv-7721 in the U.S.
`
`District Court for the District of New Jersey (Jun. 5, 2020). Petitioner is not a party
`
`to this action. Petitioner has filed inter partes review petitions (which have been
`
`instituted) on related U.S. Patent Nos. 9,211,253 and 9,467,747, which are listed in
`
`the Orange Book as covering Narcan® nasal spray (naloxone).
`
`III.
`
`Identification of Lead and Back-Up Counsel Under 37 C.F.R. §
`42.8(b)(3)
`
`Petitioner provides the following designation of counsel:
`
`Lead Counsel
`
`
`Dr. Yelee Y. Kim (Reg. No. 60,088)
`Telephone: 202.857.6147
`Fax: 202.857.6395
`Yelee.Kim@arentfox.com
`
`
`
`Back-Up Counsel
`
`
`Janine A. Carlan (Reg. No. 42,387)
`Telephone: 202.715.8506
`Fax: 202.857.6395
`Janine.Carlan@arentfox.com
`
`Richard Berman (Reg. No. 39,107)
`Telephone: 202.857.6232
`Fax: 202.857.6395
`Richard.Berman@arentfox.com
`
`Bradford Frese (Reg. No. 69,772)
`Telephone: 202.857.6496
`Fax: 202.857.6395
`Bradford.Frese@arentfox.com
`
`
`AFDOCS/22424524.1
`
`
`
`
`IPR2019-00694 – U.S. Patent No. 9,629,965
` Petitioner’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8
`
`
`
`Lead Counsel
`
`Back-Up Counsel
`Christopher Yaen (Reg. No. 66,563)
`Telephone: 202.350.3760
`Fax: 202.857.6395
`Christopher.Yaen@arentfox.com
`
`
`IV. Service Information Under 37 C.F.R. § 42.8(b)(4)
`
`Please address all correspondence to above-identified counsel at:
`
`ARENT FOX LLP
`1717 K Street NW
`Washington D.C. 20006
`Petitioner consents to electronic service.
`
`
`
`Date: June 26, 2020
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`/s/ Yelee Y. Kim
`Yelee Y. Kim, Reg. No. 60,088
`ARENT FOX LLP
`1717 K Street, NW
`Washington, DC 20006
`202.857.6000
`Counsel for Petitioner
`Nalox-1 Pharmaceuticals, LLC
`
`
`AFDOCS/22424524.1
`
`
`
`
`
`
`IPR2019-00694 – U.S. Patent No. 9,629,965
` Petitioner’s Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8
`
`
`CERTIFICATION OF SERVICE (37 C.F.R. §§ 42.6(e), 42.105(a))
`The undersigned hereby certifies that the above-captioned “Petitioner’s
`
`Updated Mandatory Notices Pursuant to 37 C.F.R. § 42.8,” was served in its entirety
`
`on June 26, 2020, upon the following parties via e-mail:
`
`Jessamyn S. Berniker (jberniker@wc.com)
`Ana C. Reyes (areyes@wc.com)
`David M. Krinsky (dkrinsky@wc.com)
`Anthony H. Sheh (asheh@wc.com)
`WILLIAMS & CONNOLLY LLP
`725 Twelfth Street, NW
`Washington, DC 20005
`(202) 434-5000
`Counsel for Patent Owner
`Adapt Pharma Operations Limited
`
`Jessica Tyrus Mackay (jmackay@greengriffith.com)
`Ann K. Kotze (akotze@greengriffith.com)
`GREEN, GRIFFITH & BORG-BREEN, LLP
`676 North Michigan Avenue, Suite 3900
`Chicago, IL 60611
`(313) 883-8000
`Counsel for Patent Owner
`Opiant Pharmaceuticals, Inc.
`
`
`
`
`
`
`
`
`
`
`
`/s/ Yelee Y. Kim
`Yelee Y. Kim, Reg. No. 60,088
`ARENT FOX LLP
`1717 K Street, NW
`Washington, D.C. 20006
`(202) 857-6000
`yelee.kim@arentfox.com
`
`
`
`Counsel for Petitioner
`Nalox-1 Pharmaceuticals, LLC
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`AFDOCS/22424524.1
`
`
`